{
    "organizations": [],
    "uuid": "ddc3fed4140c146bde79ebd9e5172199d97ef512",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-ablynxs-board-says-takeover-propos/brief-ablynxs-board-says-takeover-proposal-from-novo-nordisk-undervalues-company-idUSASM000HTR",
    "ord_in_thread": 0,
    "title": "BRIEF-Ablynx's Board Says Takeover Proposal From Novo Nordisk Undervalues Company",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 8 (Reuters) - ABLYNX NV:\n* BOARD UNANIMOUSLY CONCLUDED THAT PROPOSAL FUNDAMENTALLY UNDERVALUES ABLYNX AND ITS STRONG PROSPECTS FOR CONTINUED GROWTH AND VALUE CREATION\n* TODAY CONFIRMED THAT ON DEC 22, 2017 IT RECEIVED UNSOLICITED CONDITIONAL PROPOSAL FROM NOVO NORDISK A/S\n* J.P. MORGAN IS SERVING AS FINANCIAL ADVISOR TO ABLYNX * ABLYNX STRONGLY BELIEVES UNSOLICITED CONDITIONAL PROPOSAL FROM NOVO NORDISK FUNDAMENTALLY UNDERVALUES THE COMPANY AND ITS FUTURE PROSPECTS\n* CO LONG-TERM STRATEGIC PLAN OF BECOMING FULLY INTEGRATED BIOPHARMACEUTICAL COMPANY\n* “BOARD SEES NO MERIT IN CEDING CONTROL OF ITS ASSETS WITHOUT FULL UPFRONT VALUE RECOGNITION FOR SHAREHOLDERS” - CEO Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-08T20:43:00.000+02:00",
    "crawled": "2018-01-09T16:49:22.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "ablynx",
        "nv",
        "board",
        "unanimously",
        "concluded",
        "proposal",
        "fundamentally",
        "undervalues",
        "ablynx",
        "strong",
        "prospect",
        "continued",
        "growth",
        "value",
        "creation",
        "today",
        "confirmed",
        "dec",
        "received",
        "unsolicited",
        "conditional",
        "proposal",
        "novo",
        "nordisk",
        "morgan",
        "serving",
        "financial",
        "advisor",
        "ablynx",
        "ablynx",
        "strongly",
        "belief",
        "unsolicited",
        "conditional",
        "proposal",
        "novo",
        "nordisk",
        "fundamentally",
        "undervalues",
        "company",
        "future",
        "prospect",
        "co",
        "strategic",
        "plan",
        "becoming",
        "fully",
        "integrated",
        "biopharmaceutical",
        "company",
        "board",
        "see",
        "merit",
        "ceding",
        "control",
        "asset",
        "without",
        "full",
        "upfront",
        "value",
        "recognition",
        "shareholder",
        "ceo",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}